Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence.
Hepatitis B vaccine-induced antibodies (anti-HBs) were quantified in 35 subjects (study group) and in an additional 24-59 subjects (controls) during a period of 82 months after vaccination against hepatitis B and the values used as a basis to develop a logarithmic formula to describe the post-booster antibody kinetics. The actual anti-HBs titres are shown to be proportional to the peak titre one month post-booster but inversely proportional to the number of months between the time of booster and of retesting. Using this model and an anti-HBs quantification more than a month post-booster, the individual persistence of vaccine-induced anti-HBs antibodies can be calculated.
Gesemann
M
M
Institut für Laboratoriumsmedizin, St Markus-Krankenhaus, Frankfurt am Main, Germany.
Scheiermann
N
N
D000328:Adult; D006510:Hepatitis B Antibodies / Q000096:biosynthesis / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008432:Mathematical Computing; D008954:Models, Biological; D011237:Predictive Value of Tests; D011446:Prospective Studies
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines